ClinicalTrials.gg
CompletedNCT00443456Updated Oct 28, 2009Results posted

Long Term Study Of Amlodipine 10mg With Hypertension For Whom Amlodipine 5mg Is Insufficient

A Phase 3 interventional study of Amlodipine in Hypertension, sponsored by Pfizer. Completed at 9 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2009-10-28.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
134
Allocation
Non-randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.

Enrollment
110th of 186
134 · median 180
Started
2007
with 16 others
Phase 3
69 of 187
2 open now
Registered
40th of 187
by date

Among the 187 studies testing amlodipine in Hypertension, this one is the 110th largest by enrollment of the 186 interventional ones that give a count, is one of 17 that started in 2007, is one of 69 in phase 3, and was the 40th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About amlodipine

Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing amlodipine in Hypertension, or all of them as a file.
02

Study summary

To investigate the safety and efficacy of the long-term use of amlodipine 10 mg in subjects who will be able to enter a long-term study after completing the parent study "A double-blind comparative study between amlodipine 5 mg and 10 mg in patients with essential hypertension for whom amlodipine 5 mg is insufficiently effective" (Protocol No.: A0531085).

Read the detailed description

NCT00415623 (protocol A0531085)

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who had completed the preceding study A0531085, Phase III study, who the investigator judged to be able to further treatment of long term administration in terms of efficacy and safety
  • Patients who had a treatment compliance rate of at least 80%

Exclusion criteria

Exclusion Criteria:

  • The patient who met the discontinuation criteria in the preceding study A0531085
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Single

    Drug: Amlodipine

Interventions

  • Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks

06

What researchers measure

Primary outcomes

  1. Change in Systolic Blood Pressure From Baseline of the Preceding Study

    Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)

    Time frame: Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

  2. Change in Systolic Blood Pressure From Baseline of This Long-term Study

    Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)

    Time frame: Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

  3. Change in Diastolic Blood Pressure From Baseline of the Preceding Study

    Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)

    Time frame: Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

  4. Change in Diastolic Blood Pressure From Baseline of This Long-term Study

    Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)

    Time frame: Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

  5. Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value

    Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg

    Time frame: 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

  6. Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value and Systolic Blood Pressure Had Decreased by 10 mmHg or More From Baseline in the Preceding Study

    Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg

    Time frame: 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

Other outcomes

  1. Change in Systolic Blood Pressure From Baseline of the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent

    Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)

    Time frame: Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

  2. Change in Systolic Blood Pressure From Baseline of This Long-term Study in Treatment Groups With or Without Concomitant Antihypertensive Agent

    Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)

    Time frame: Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

  3. Change in Diastolic Blood Pressure From Baseline of the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent

    Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)

    Time frame: Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

  4. Change in Diastolic Blood Pressure From Baseline of This Long-term Study in Treatment Groups With or Without Concomitant Antihypertensive Agent

    Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)

    Time frame: Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

  5. Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value in Treatment Groups With or Without Concomitant Antihypertensive Agent

    Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg

    Time frame: 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

  6. Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value and Systolic Blood Pressure Had Decreased by 10 mmHg or More From Baseline in the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent

    Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg

    Time frame: 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks

07

Results

Posted Oct 9, 2009

Participant flow

Participant flow — Overall Study
MilestoneAmlodipine
Started134
Completed116
Not completed18
Withdrew: Adverse event16
Withdrew: Move1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryChange in Systolic Blood Pressure From Baseline of the Preceding Study

Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)

Time frame:
Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure From Baseline of the Preceding Study
mmHgAmlodipineThe Preceding Study 5 mg Sub-set of This Long-term StudyThe Preceding Study 10 mg Sub-set of This Long-term Study
Week 0: Baseline (Actual Value)148.8 ± 8.3148.8 ± 8.0148.8 ± 8.7
Week 8-8.7 ± 12.0-5.6 ± 12.9-12.0 ± 10.1
Week 10-14.8 ± 11.5-14.5 ± 11.3-15.0 ± 11.8
Week 12-15.6 ± 10.0-15.6 ± 9.7-15.7 ± 10.4
Week 16-16.7 ± 10.7-16.9 ± 10.5-16.4 ± 10.9
Week 20-15.8 ± 10.4-17.4 ± 11.1-14.1 ± 9.4
Week 24-15.4 ± 11.2-16.1 ± 10.5-14.6 ± 11.9
Week 28-14.7 ± 11.3-15.7 ± 11.7-13.6 ± 11.0
Week 32-13.8 ± 12.7-14.4 ± 12.4-13.2 ± 13.2
Week 36-13.4 ± 12.3-14.6 ± 12.0-12.2 ± 12.6
Week 40-13.9 ± 11.4-14.7 ± 11.6-13.0 ± 11.1
Week 44-15.7 ± 12.1-15.6 ± 12.5-15.8 ± 11.8
Week 48-15.3 ± 11.4-16.0 ± 11.6-14.5 ± 11.2
Week 52-15.6 ± 11.5-15.0 ± 11.7-16.3 ± 11.3
PrimaryChange in Systolic Blood Pressure From Baseline of This Long-term Study

Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)

Time frame:
Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure From Baseline of This Long-term Study
mmHgAmlodipineThe Preceding Study 5 mg Sub-set of This Long-term StudyThe Preceding Study 10 mg Sub-set of This Long-term Study
Week 8: Baseline (Actual Value)140.1 ± 14.2143.2 ± 15.7136.8 ± 11.6
Week 10-6.0 ± 10.9-8.9 ± 11.2-3.0 ± 9.8
Week 12-6.9 ± 11.9-10.0 ± 13.6-3.7 ± 8.8
Week 16-8.0 ± 12.0-11.3 ± 13.3-4.4 ± 9.4
Week 20-7.1 ± 12.0-11.8 ± 12.7-2.1 ± 9.0
Week 24-6.7 ± 12.4-10.5 ± 12.7-2.6 ± 10.8
Week 28-6.0 ± 13.0-10.1 ± 13.9-1.6 ± 10.3
Week 32-5.1 ± 12.2-8.8 ± 13.0-1.2 ± 9.9
Week 36-4.7 ± 12.6-9.0 ± 13.2-0.2 ± 10.4
Week 40-5.2 ± 13.7-9.1 ± 14.9-1.0 ± 10.9
Week 44-7.0 ± 12.6-10.0 ± 14.1-3.8 ± 10.0
Week 48-6.6 ± 13.4-10.4 ± 14.4-2.5 ± 10.9
Week 52-6.9 ± 13.0-9.4 ± 14.0-4.3 ± 11.4
PrimaryChange in Diastolic Blood Pressure From Baseline of the Preceding Study

Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)

Time frame:
Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure From Baseline of the Preceding Study
mmHgAmlodipineThe Preceding Study 5 mg Sub-set of This Long-term StudyThe Preceding Study 10 mg Sub-set of This Long-term Study
Week 0: Baseline (Actual Value)86.3 ± 10.287.6 ± 10.084.8 ± 10.2
Week 8-3.1 ± 8.8-1.8 ± 9.4-4.5 ± 7.9
Week 10-6.4 ± 7.9-6.6 ± 7.7-6.3 ± 8.1
Week 12-6.9 ± 7.6-7.7 ± 7.9-6.0 ± 7.2
Week 16-7.3 ± 8.0-8.4 ± 8.0-6.2 ± 7.9
Week 20-7.2 ± 8.0-7.9 ± 8.0-6.4 ± 7.9
Week 24-6.8 ± 8.1-7.1 ± 8.6-6.5 ± 7.6
Week 28-6.8 ± 8.3-7.8 ± 8.9-5.7 ± 7.5
Week 32-6.8 ± 8.6-7.1 ± 8.5-6.5 ± 8.8
Week 36-6.5 ± 8.4-7.4 ± 7.9-5.5 ± 8.9
Week 40-6.8 ± 8.7-7.2 ± 9.6-6.3 ± 7.8
Week 44-7.3 ± 8.0-7.6 ± 8.2-6.9 ± 7.8
Week 48-7.2 ± 8.8-7.3 ± 9.4-7.0 ± 8.2
Week 52-7.9 ± 8.5-8.2 ± 7.9-7.7 ± 9.2
PrimaryChange in Diastolic Blood Pressure From Baseline of This Long-term Study

Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)

Time frame:
Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure From Baseline of This Long-term Study
mmHgAmlodipineThe Preceding Study 5 mg Sub-set of This Long-term StudyThe Preceding Study 10 mg Sub-set of This Long-term Study
Week 8: Baseline (Actual Value)83.1 ± 11.585.8 ± 11.880.3 ± 10.5
Week 10-3.3 ± 7.2-4.8 ± 7.5-1.7 ± 6.6
Week 12-3.7 ± 7.3-5.8 ± 8.1-1.5 ± 5.6
Week 16-4.2 ± 7.9-6.5 ± 8.3-1.7 ± 6.6
Week 20-4.1 ± 7.5-6.1 ± 8.3-1.9 ± 5.8
Week 24-3.7 ± 8.4-5.3 ± 8.4-2.0 ± 8.2
Week 28-3.7 ± 8.3-6.0 ± 8.8-1.2 ± 6.9
Week 32-3.6 ± 8.4-5.2 ± 8.3-1.9 ± 8.3
Week 36-3.3 ± 9.2-5.6 ± 9.1-0.9 ± 8.7
Week 40-3.6 ± 9.1-5.4 ± 9.8-1.7 ± 8.0
Week 44-4.1 ± 8.3-5.8 ± 8.7-2.3 ± 7.4
Week 48-4.1 ± 8.7-5.5 ± 9.5-2.5 ± 7.6
Week 52-4.8 ± 9.6-6.3 ± 9.5-3.2 ± 9.5
Other pre-specifiedChange in Systolic Blood Pressure From Baseline of the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent

Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)

Time frame:
Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure From Baseline of the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
mmHgSubjects With Concomitant Antihypertensive AgentSubjects Without Concomitant Antihypertensive Agent
Week 0: Baseline (Actual Value)153.9 ± 10.8148.3 ± 7.9
Week 8 (n=13, 121)-4.8 ± 8.1-9.1 ± 12.3
Week 10 (n=13, 118)-13.8 ± 8.7-14.8 ± 11.8
Week 12 (n=12, 119)-13.5 ± 8.0-15.8 ± 9.9
Week 16 (n=12, 117)-17.2 ± 8.9-16.4 ± 10.5
Week 20 (n=12, 116)-10.8 ± 6.0-16.1 ± 10.3
Week 24 (n=11, 113)-13.8 ± 14.0-14.8 ± 10.2
Week 28 (n=12, 111)-15.1 ± 10.9-13.6 ± 10.4
Week 32 (n=12, 111)-4.8 ± 13.9-14.0 ± 11.7
Week 36 (n=11, 108)-4.8 ± 13.2-13.1 ± 11.5
Week 40 (n=12, 108)-9.6 ± 8.3-13.6 ± 10.9
Week 44 (n=11, 108)-13.7 ± 8.3-15.4 ± 12.0
Week 48 (n=9, 107)-11.1 ± 12.5-15.3 ± 10.6
Week 52 (n=9, 106)-10.8 ± 8.5-15.9 ± 11.0
Other pre-specifiedChange in Systolic Blood Pressure From Baseline of This Long-term Study in Treatment Groups With or Without Concomitant Antihypertensive Agent

Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)

Time frame:
Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure From Baseline of This Long-term Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
mmHgSubjects With Concomitant Antihypertensive AgentSubjects Without Concomitant Antihypertensive Agent
Week 8: Baseline (Actual Value)149.1 ± 15.1139.2 ± 13.8
Week 10 (n=13, 118)-9.0 ± 9.0-5.9 ± 11.2
Week 12 (n=12, 119)-8.4 ± 9.2-6.9 ± 12.2
Week 16 (n=12, 117)-12.0 ± 9.8-7.6 ± 12.3
Week 20 (n=12, 116)-5.6 ± 8.6-7.3 ± 12.3
Week 24 (n=11, 113)-9.2 ± 15.4-6.2 ± 12.1
Week 28 (n=12, 111)-9.9 ± 13.1-5.0 ± 12.7
Week 32 (n=12, 111)0.4 ± 17.5-5.3 ± 11.5
Week 36 (n=11, 108)0.2 ± 18.7-4.5 ± 12.0
Week 40 (n=12, 108)-4.5 ± 11.2-5.2 ± 14.1
Week 44 (n=11, 108)-9.1 ± 13.2-7.1 ± 12.6
Week 48 (n=9, 107)-7.3 ± 17.4-7.0 ± 13.2
Week 52 (n=9, 106)-7.1 ± 13.9-7.5 ± 13.1
Other pre-specifiedChange in Diastolic Blood Pressure From Baseline of the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent

Value at each observation time point minus value at Week 0 (Week 0 was defined as baseline of the preceding study A0531085: NCT00415623.)

Time frame:
Week 0, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure From Baseline of the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
mmHgSubjects With Concomitant Antihypertensive AgentSubjects Without Concomitant Antihypertensive Agent
Week 0: Baseline (Actual Value)85.9 ± 12.486.3 ± 10.0
Week 8 (n=13, 121)0.3 ± 9.9-3.5 ± 8.6
Week 10 (n=13, 118)-3.6 ± 9.1-6.6 ± 7.7
Week 12 (n=12, 119)-4.8 ± 9.7-7.0 ± 7.4
Week 16 (n=12, 117)-4.9 ± 9.2-7.6 ± 8.0
Week 20 (n=12, 116)-2.5 ± 9.3-7.7 ± 7.9
Week 24 (n=11, 113)-2.9 ± 10.3-6.9 ± 8.1
Week 28 (n=12, 111)-3.2 ± 7.5-6.9 ± 8.6
Week 32 (n=12, 111)1.7 ± 7.6-7.4 ± 8.6
Week 36 (n=11, 108)2.1 ± 8.6-7.0 ± 8.2
Week 40 (n=12, 108)0.8 ± 6.8-7.3 ± 8.8
Week 44 (n=11, 108)-2.4 ± 7.0-7.5 ± 8.2
Week 48 (n=9, 107)-0.8 ± 9.4-7.5 ± 9.0
Week 52 (n=9, 106)-2.7 ± 7.3-8.4 ± 8.9
Other pre-specifiedChange in Diastolic Blood Pressure From Baseline of This Long-term Study in Treatment Groups With or Without Concomitant Antihypertensive Agent

Value at each observation time point minus value at Week 8 (Week 8 was defined as baseline of this long-term study A0531086: NCT00443456.)

Time frame:
Week 8, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure From Baseline of This Long-term Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
mmHgSubjects With Concomitant Antihypertensive AgentSubjects Without Concomitant Antihypertensive Agent
Week 8: Baseline (Actual Value)86.2 ± 11.882.8 ± 11.4
Week 10 (n=13, 118)-3.9 ± 5.4-3.3 ± 7.5
Week 12 (n=12, 119)-5.0 ± 4.9-3.7 ± 7.6
Week 16 (n=12, 117)-5.1 ± 5.0-4.2 ± 8.2
Week 20 (n=12, 116)-2.8 ± 6.4-4.4 ± 7.7
Week 24 (n=11, 113)-4.0 ± 8.4-3.6 ± 8.7
Week 28 (n=12, 111)-3.5 ± 8.6-3.6 ± 8.4
Week 32 (n=12, 111)1.5 ± 9.8-4.2 ± 8.4
Week 36 (n=11, 108)2.3 ± 11.8-3.8 ± 9.2
Week 40 (n=12, 108)0.6 ± 6.6-4.1 ± 9.6
Week 44 (n=11, 108)-3.4 ± 9.2-4.4 ± 8.5
Week 48 (n=9, 107)-1.9 ± 11.0-4.6 ± 8.9
Week 52 (n=9, 106)-3.8 ± 10.2-5.4 ± 10.1
PrimaryNumber of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value

Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg

Time frame:
8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Number · participants
Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value
participantsAmlodipineThe Preceding Study 5 mg Sub-set of This Long-term StudyThe Preceding Study 10 mg Sub-set of This Long-term Study
Week 8411526
Week 10592732
Week 12643034
Week 16622933
Week 20653530
Week 24643232
Week 28543024
Week 32532330
Week 36563224
Week 40562927
Week 44582632
Week 48583127
Week 52632934
PrimaryNumber of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value and Systolic Blood Pressure Had Decreased by 10 mmHg or More From Baseline in the Preceding Study

Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg

Time frame:
8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Number · participants
Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value and Systolic Blood Pressure Had Decreased by 10 mmHg or More From Baseline in the Preceding Study
participantsAmlodipineThe Preceding Study 5 mg Sub-set of This Long-term StudyThe Preceding Study 10 mg Sub-set of This Long-term Study
Week 8361323
Week 10552530
Week 12602931
Week 16592831
Week 20623527
Week 24603030
Week 28543024
Week 32502228
Week 36543222
Week 40522725
Week 44572532
Week 48563026
Week 52602832
Other pre-specifiedNumber of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value in Treatment Groups With or Without Concomitant Antihypertensive Agent

Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg

Time frame:
8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Number · participants
Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value in Treatment Groups With or Without Concomitant Antihypertensive Agent
participantsSubjects With Concomitant Antihypertensive AgentSubjects Without Concomitant Antihypertensive Agent
Week 8 (n=13, 121)239
Week 10 (n=13, 118)354
Week 12 (n=12, 119)459
Week 16 (n=12, 117)456
Week 20 (n=12, 116)359
Week 24 (n=11, 113)257
Week 28 (n=12, 111)246
Week 32 (n=12, 111)246
Week 36 (n=11, 108)245
Week 40 (n=12, 108)148
Week 44 (n=11, 108)149
Week 48 (n=9, 107)149
Week 52 (n=9, 106)154
Other pre-specifiedNumber of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value and Systolic Blood Pressure Had Decreased by 10 mmHg or More From Baseline in the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent

Target blood pressure reduction value in accordance with Japanese Society of Hypertension Guidelines for the Management of Hypertension 2004: For \<= 64 years old: systolic blood pressure below 130 mmHg and diastolic blood pressure below 85 mmHg; For \>= 65 years old: systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg

Time frame:
8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks and 52 weeks
Reported as:
Number · participants
Number of Subjects Whose Blood Pressure Reached Target Blood Pressure Reduction Value and Systolic Blood Pressure Had Decreased by 10 mmHg or More From Baseline in the Preceding Study in Treatment Groups With or Without Concomitant Antihypertensive Agent
participantsSubjects With Concomitant Antihypertensive AgentSubjects Without Concomitant Antihypertensive Agent
Week 8 (n=13, 121)135
Week 10 (n=13, 118)350
Week 12 (n=12, 119)455
Week 16 (n=12, 117)453
Week 20 (n=12, 116)356
Week 24 (n=11, 113)253
Week 28 (n=12, 111)246
Week 32 (n=12, 111)243
Week 36 (n=11, 108)243
Week 40 (n=12, 108)144
Week 44 (n=11, 108)148
Week 48 (n=9, 107)147
Week 52 (n=9, 106)151

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Amlodipine—8/134 (6%)50/134 (37.3%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventAmlodipine
FallInjury, poisoning and procedural complications2/134
Loss of consciousnessNervous system disorders2/134
Angina unstableCardiac disorders1/134
Atrioventricular blockCardiac disorders1/134
Sick sinus syndromeCardiac disorders1/134
Subdural haematomaInjury, poisoning and procedural complications1/134
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/134
Gum neoplasm malignant stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/134
Malignant ascitesNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/134
Cerebral infarctionNervous system disorders1/134
Most frequent other events
Most frequent other events
EventAmlodipine
NasopharyngitisInfections and infestations33/134
Oedema peripheralGeneral disorders15/134
Back painMusculoskeletal and connective tissue disorders9/134

Baseline characteristics

Age, Customized
Age, Customized(participants)Amlodipine
20 to 44 years13
45 to 64 years65
>=65 years56
Sex: Female, Male
Sex: Female, Male(Participants)Amlodipine
Female61
Male73
08

Study locations

9 sites
  • Pfizer Investigational Site
    Chikushino, Fukuoka, Japan
  • Pfizer Investigational Site
    Kitakyushu, Fukuoka, Japan
  • Pfizer Investigational Site
    Yokohama, Kanagawa, Japan
  • Pfizer Investigational Site
    Iruma, Saitama, Japan
  • Pfizer Investigational Site
    Koshigaya, Saitama, Japan
  • Pfizer Investigational Site
    Edogawa-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Setagaya-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Sumida-ku, Tokyo, Japan
  • Pfizer Investigational Site
    Fukuoka, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2007
First posted
Mar 6, 2007
Start
May 2007
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Oct 9, 2009
Last update
Oct 28, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00443456
Lead sponsor
Pfizer
First posted
Mar 6, 2007
Start date
May 2007
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Oct 9, 2009
Last update
Oct 28, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlodipine

Start the discussion